ftInvstr
JUBLPHARMA · Healthcare ₹930.0 +2.21% Mkt Cap ₹14662 Cr

JUBLPHARMA

Healthcare Drug Manufacturers - Specialty & Generic
₹930.0
+2.21% today · 30d +0.22%
as of 2026-09-04
Price · Daily Candles
AI narrative is temporarily unavailable for JUBLPHARMA. The deterministic sections below render from live data.
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹2229 Cr
+17.29% YoY
NET PROFIT
₹56 Cr
-44.98% YoY
OPM
11.91%
-3.86pp YoY
EPS
₹3.57
PE 42.83
Intrinsic value · DCF: N/A — Company is currently free-cash-flow negative (-1.5% of mktcap). DCF assumes a going concern generating positive cash flow; a meaningful intrinsic value can only be computed once FCF turns positive. Use the Strategy Fit and ML sections instead.
◇ Sector Position
PEERPEROCE %
JUBLPHARMA42.8310.0
SUNPHARMA37.5721.44
DIVISLAB89.1821.56
ZYDUSLIFE24.6424.22
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
56
SCORE / 100
Overall
6-axis composite of the sections below.
Performance NEUTRAL 40
Valuation FAIR 40
Growth STEADY 54
Profitability DECENT 58
Technicals NEUTRAL 55
Risk LOW 90
Key Stats
TTM PE
42.83
P/B
2.12
52W HIGH
₹1184.8
OFF HIGH
-21.51%
DIV YIELD
0.54%
MKT CAP
₹14662 Cr
◉ Active Signals
MACDNeutral7.6277
RSI(14)Neutral56.55
Street Consensus
2 analysts
₹1088.5
mean target
Low ₹850.0Now ₹930.0High ₹1327.0
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold JUBLPHARMA and at what entry.

Sign up freeSign in